SS
LXEO icon

Sunbelt Securities’s Lexeo Therapeutics LXEO Stock Holding History

Sunbelt Securities’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92 Hold
16
– – ﹤0.01% 2680
2025
Q4 		$159 Hold
16
– – ﹤0.01% 2470
2025
Q3 		$106 Buy
+16
New +$77 ﹤0.01% 2503

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sunbelt Securities's LXEO Position: Q1 2026 in Review

Sunbelt Securities held its Lexeo Therapeutics (LXEO) position steady in Q1 2026 at 16 shares worth $92. The position accounts for ﹤0.01% of the portfolio, ranked #2680.

Sunbelt Securities first reported a position in LXEO in Q3 2025 and has held it in 3 quarters since. The position peaked at $159 in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Sunbelt Securities held 16 shares of Lexeo Therapeutics worth $92 as of Q1 2026.
  • Sunbelt Securities left its Lexeo Therapeutics share count unchanged in Q1 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2680 holding.
  • Sunbelt Securities first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Sunbelt Securities's Lexeo Therapeutics position peaked at $159 in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.